Reviewing the Diagnostic Performance of 99mTc-TRODAT-1 Imaging in Distinguishing Idiopathic Parkinson's Disease from Parkinson-Plus Syndromes

Abstract

Aim Diagnosing movement disorders can be challenging owing to their similar clinical presentations with other neurodegenerative and basal ganglia disorders, like idiopathic Parkinson's disease (IPD), essential tremors (ET), vascular parkinsonism, multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). Technetium-99m labeled tropane derivative (99mTc-TRODAT-1) imaging can help in diagnosing Parkinson's disease at an early stage to help early initiation of the treatment. The current study aimed to evaluate the role of 99mTc-TRODAT-1 imaging in differentiating IPD and Parkinson-plus syndromes (PPS).

Material and Methods We have analyzed 38 patients, referred to our department for 99mTc-TRODAT imaging. These patients were thoroughly evaluated in the movement disorder clinic at our institute and had a possible/ probable diagnosis of IPD, Hoehn and Yahr (H&Y) stage I/II (n = 28) or PPS (PSP [n = 06] and MSA [n = 04]). Striatal uptake ratio (SUR) was calculated in all the patients and data was statistically analyzed.

Results The mean age of IPD, PSP, and MSA groups was 56.5 ± 12.15, 65.2 ± 11.1, and 51.2 ± 3.9 years, respectively. On qualitative evaluation, all patients had reduced striatal uptake on 99mTc-TRODAT imaging, with 31/38 patients showed a greater reduction in putaminal uptake compared with the caudate nucleus. On semiquantitative evaluation, mean total SUR was 0.58 ± 0.27, 0.53 ± 0.31, and 0.91 ± 0.20 in IPD, PSP, and MSA groups, respectively. The total SUR was lowest in the PSP group followed by IPD, but MSA had relatively higher SUR, although the difference was not statistically significant. Among the IPD patient group, 25/28 patients (89.3%) experienced a greater reduction in SUR values in the striatum contralateral to the side, where motor symptoms first manifested at disease onset.

Conclusion 99mTc-TRODAT is a potential imaging biomarker for the evaluation of presynaptic dopaminergic dysfunction in patients with movement disorders. In our study cohort, mean SUR values were lowest for the PSP group followed by IPD and MSA group, which was in concordance with previous studies. However, the difference between SUR values in these two groups was not statistically significant. The present study emphasizes that the capacity of 99mTc-TRODAT-1 imaging alone for diagnosing IPD from PPS is constrained, although it offers a precise approach for distinguishing patients with IPD from those with essential tremors, drug-induced, or psychogenic parkinsonism. Consequently, more specific imaging biomarkers are needed to effectively differentiate between patients with IPD and those with PPS.

Keywords

99mTc-TRODAT-1 - idiopathic Parkinson's disease - Parkinson-plus syndrome - movement disorders - parkinsonism

Previous Presentation

This research was previously presented as an Oral Presentation in Society of Nuclear Medicine, Hyderabad, India on December 16–18, 2021.

Publikationsverlauf

Artikel online veröffentlicht:
04. Juli 2024

• References

• 1 Ostrem JL, Galifianakis NB. Overview of common movement disorders. Continuum (Minneap Minn) 2010; 16 (1 Movement Disorders): 13-48
• 2 Shinto AS, Antony J, Kamaleshwaran K. et al. Correlative (99m)tc-labeled tropane derivative single photon emission computer tomography and clinical assessment in the staging of Parkinson disease. World J Nucl Med 2014; 13 (03) 178-183
• 3 Mittal BR, Sood A, Shukla J. et al. 99mTc-TRODAT-1 SPECT/CT imaging as a complementary biomarker in the diagnosis of parkinsonian syndromes. Nucl Med Commun 2018; 39 (04) 312-318
• 4 Wang J, Jiang YP, Liu XD. et al. 99mTc-TRODAT-1 SPECT study in early Parkinson's disease and essential tremor. Acta Neurol Scand 2005; 112 (06) 380-385
• 5 Jameson JL, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. eds. Harrison's Principles of Medicine. 20th ed.. New York: McGraw Hill, Health Professions Division; 2020: 1007-1014
• 6 Gilman S, Wenning GK, Low PA. et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 2008; 71 (09) 670-676
• 7 Weng YH, Yen TC, Chen MC. et al. Sensitivity and specificity of 99m Tc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects the imaging of dopamine transporter (DAT) with 99m. J Nucl Med 2004; 45 (03) 393-401
• 8 Morbelli S, Esposito G, Arbizu J. et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging 2020; 47 (08) 1885-1912
• 9 Weng YH, Yen TC, Chen MC. et al. Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects. J Nucl Med 2004; 45 (03) 393-401
• 10 Van Laere K, Varrone A, Booij J. et al. EANM procedure guidelines for brain neurotransmission SPECT/PET using dopamine D2 receptor ligands, version 2. Eur J Nucl Med Mol Imaging 2010; 37 (02) 434-442
• 11 Marsili L, Rizzo G, Colosimo C. Diagnostic criteria for Parkinson's disease: from James Parkinson to the concept of prodromal disease. Front Neurol 2018; 9 (MAR): 156
• 12 Fallahi B, Esmaeili A, Beiki D. et al. Evaluation of (99m)Tc-TRODAT-1 SPECT in the diagnosis of Parkinson's disease versus other progressive movement disorders. Ann Nucl Med 2016; 30 (02) 153-162
• 13 Sood A, Shukla J, Shree R, Vatsa R, Modi M, Mittal BR. Comparative performance of 99mTc-TRODAT-1 SPECT/CT and 18F-FDOPA PET/CT imaging in patients with Parkinson's disease, Parkinson-plus syndrome, and essential tremor. Clin Nucl Med 2021; 46 (02) 95-102
• 14 Gupta V, Ranjan R, Verma R, Belho ES, Malik D, Mahajan H. Correlation of 99mTc-TRODAT-1 SPECT imaging findings and clinical staging of Parkinson disease. Clin Nucl Med 2019; 44 (05) 347-350
• 15 Swanson RL, Newberg AB, Acton PD. et al. Differences in [99mTc]TRODAT-1 SPECT binding to dopamine transporters in patients with multiple system atrophy and Parkinson's disease. Eur J Nucl Med Mol Imaging 2005; 32 (03) 302-307
• 16 Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss WD. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry 2002; 73 (05) 517-523
• 17 Antonini A, Benti R, De Notaris R. et al. 123I-Ioflupane/SPECT binding to striatal dopamine transporter (DAT) uptake in patients with Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Neurol Sci 2003; 24 (03) 149-150
• 18 Antonini A, Leenders KL, Vontobel P. et al. Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. Brain 1997; 120 (Pt 12): 2187-2195
• 19 Brücke T, Djamshidian S, Bencsits G, Pirker W, Asenbaum S. Podreka I. SPECT and PET imaging of the dopaminergic system in Parkinson's disease. J Neurol 2000; 247 (04) 2-7
• 20 Suwijn SR, de Bruin K, de Bie RM, Booij J. The role of SPECT imaging of the dopaminergic system in translational research on Parkinson's disease. Parkinsonism Relat Disord 2014; 20 (Suppl. 01) S184-S186
• 21 Geng Y, Shi GH, Jiang Y, Xu LX, Hu XY, Shao YQ. Investigating the role of 99mTc-TRODAT-1 SPECT imaging in idiopathic Parkinson's disease. J Zhejiang Univ Sci B 2005; 6 (01) 22-27
• 22 Birman N, Lorberboym M, Lampl Y, Djaldetti R. Decreased dopamine transporter binding ipsilateral to the clinically more affected side in Parkinson's disease: which side to take?. J Neurol Neurophysiol 2016; 7: 2
• 23 Benamer HTS, Oertel WH, Patterson J. et al. Prospective study of presynaptic dopaminergic imaging in patients with mild parkinsonism and tremor disorders: part 1. Baseline and 3-month observations. Mov Disord 2003; 18 (09) 977-984
• 24 Tripathi M, Kumar A, Bal C. Neuroimaging in Parkinsonian disorders. Neurol India 2018; 66 (Supplement): S68-S78
• 25 Guedj E, Varrone A, Boellaard R, Albert NL, Barthel H, van Berckel B. et al EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3. Eur J Nucl Med Mol Imaging 2022; 49: 632-51